Engineered Measles Virus as a Novel Oncolytic Therapy Against Prostate Cancer

被引:79
作者
Msaouel, Pavlos [1 ,2 ]
Lankov, Lanko D. [1 ]
Allen, Cory [1 ]
Morrs, John C. [3 ]
von Messling, Veronika [4 ]
Cattaneo, Roberto [1 ]
Koutsilieris, Michael [2 ]
Russell, Stephen J. [1 ]
Galanis, Evanthia [1 ,5 ]
机构
[1] Mayo Clin, Dept Mol Med, Rochester, MN USA
[2] Univ Athens, Dept Expt Physiol, Athens 11528, Greece
[3] Mayo Clin, Dept Internal Med, Div Endocrinol, Rochester, MN USA
[4] Univ Quebec, Inst Armand Frappier, INRS, Laval, PQ, Canada
[5] Mayo Clin, Dept Oncol, Rochester, MN USA
关键词
CEA; measles virus; MV-CEA; prostate cancer; virotherapy; COMPLEMENT REGULATORY PROTEINS; TUMOR-CELLS; IN-VIVO; CARCINOEMBRYONIC ANTIGEN; CELLULAR RECEPTOR; VACCINE STRAIN; CD46; EXPRESSION; CARRIERS; XENOGRAFTS;
D O I
10.1002/pros.20857
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND. No curative therapy is currently available for locally advanced or metastatic Prostate cancer. Oncolytic viruses represent a novel class of therapeutic agents that demonstrates no cross-resistance with existing approaches and can therefore be combined with conventional treatment modalities. Measles virus strains deriving from the Edmonston (MV-Edm) vaccine strain have shown considerable oncolytic activity against a variety of solid turners and hematologic malignancies. In this study, we investigated the antitumor potential of recombinant MV-Edm derivatives as novel oncolytic agents against prostate cancer. METHODS. The susceptibility of prostate cancer cell lines (PC-3, DU-145, and LNCaP) to measles virus infection was demonstrated using ail MV-Edm derivative expressing green fluorescent protein (GFP). MV-Edm replication in prostate cancer cell lines was assessed by one step viral growth curves. The oncolytic effect of an MV-Edm strain engineered to express the human carcinoembryonic antigen (CEA) was demonstrated in vitro by MTT assays and in vivo in subcutaneous PC-3 xenografts. CEA levels were quantitated in cell supernatants and mouse serum samples. RESULTS. Recombinant MV-Edm strains call effectively infect, replicate in and kill prostate cancer cells. Intratumoral administration of MV-CEA at a total dose of 6 x 10(6) TCID50 resulted in statistically significant tumor growth delay (P = 0.004) and prolongation of survival (P = 0.001) in a subcutaneous PC-3 xenograft model. Viral growth kinetics paralleled CEA production. CONCLUSIONS. MV-CEA has potent antitumor activity against prostate cancer cell lines and xenografts. Viral gene expression during treatment can be determined by monitoring of CEA levels in the serum; the latter could allow dose optimization and tailoring of individualized treatment protocols. Prostate 69: 82-91, 2009. (C) 2008 Wiley-Liss. Inc.
引用
收藏
页码:82 / 91
页数:10
相关论文
共 42 条
[1]  
Allen C, 2008, EXPERT OPIN BIOL TH, V8, P213, DOI [10.1517/14712598.8.2.213, 10.1517/14712598.8.2.213 ]
[2]   High CD46 receptor density determines preferential killing of tumor cells by oncolytic measles virus [J].
Anderson, BD ;
Nakamura, T ;
Russell, SJ ;
Peng, KW .
CANCER RESEARCH, 2004, 64 (14) :4919-4926
[3]   Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma [J].
Blechacz, Boris ;
Splinter, Patrick L. ;
Greiner, Suzanne ;
Myers, Rae ;
Peng, Kah-Whye ;
Federspiel, Mark J. ;
Russell, Stephen J. ;
LaRusso, Nicholas F. .
HEPATOLOGY, 2006, 44 (06) :1465-1477
[4]   Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy [J].
Blute, ML ;
Bergstralh, EJ ;
Iocca, A ;
Scherer, B ;
Zincke, H .
JOURNAL OF UROLOGY, 2001, 165 (01) :119-125
[5]   Activated signal transducers and activators of transcription 3 signaling induces CD46 expression and protects human cancer cells from complement-dependent cytotoxicity [J].
Buettner, Ralf ;
Huang, Mei ;
Gritsko, Tanya ;
Karras, Jim ;
Enkemann, Steve ;
Mesa, Tania ;
Nam, Sangkil ;
Yu, Hua ;
Jove, Richard .
MOLECULAR CANCER RESEARCH, 2007, 5 (08) :823-832
[6]   Four viruses, two bacteria, and one receptor: Membrane cofactor protein (CD46) as pathogens' magnet [J].
Cattaneo, R .
JOURNAL OF VIROLOGY, 2004, 78 (09) :4385-4388
[7]   Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded [J].
Cattaneo, Roberto ;
Miest, Tanner ;
Shashkova, Elena V. ;
Barry, Michael A. .
NATURE REVIEWS MICROBIOLOGY, 2008, 6 (07) :529-540
[8]   SUCCESSES AND FAILURES IN MEASLES CONTROL [J].
CUTTS, FT ;
MARKOWITZ, LE .
JOURNAL OF INFECTIOUS DISEASES, 1994, 170 :S32-S41
[9]   Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter [J].
Dingli, D ;
Peng, KW ;
Harvey, ME ;
Greipp, PR ;
O'Connor, MK ;
Cattaneo, R ;
Morris, JC ;
Russell, SJ .
BLOOD, 2004, 103 (05) :1641-1646
[10]   THE HUMAN CD46 MOLECULE IS A RECEPTOR FOR MEASLES-VIRUS (EDMONSTON STRAIN) [J].
DORIG, RE ;
MARCIL, A ;
CHOPRA, A ;
RICHARDSON, CD .
CELL, 1993, 75 (02) :295-305